Crimson Publishers Publish With Us Reprints e-Books Video articles

Full Text

Research in Medical & Engineering Sciences

COVID-19 “A Novel Great Imitator” and Its Cause-Effect Relationship on the Skin

Jimmy Steven*

Hospital General San Juan de Dios, 1ra Avenida “A” 10-50, zona 1, Ciudad de Guatemala 01001, Guatemala

*Corresponding author: Jimmy Steven, Hospital General San Juan de Dios, 1ra Avenida “A” 10-50, zona 1, Ciudad de Guatemala 01001, Guatemala

Submission: June 08, 2022Published: June 13, 2022

DOI: 10.31031/RMES.2022.09.000724

ISSN: 2576-8816
Volume9 Issue5


The emergence of the new coronavirus in December 2019, the main actor in the current COVID-19 pandemic and type 2 acute respiratory distress syndrome (SARS-CoV-2), initially allowed elucidating the particular respiratory symptoms of the disease that regularly it culminated in severe respiratory distress requiring mechanical ventilation and caused death in a considerable percentage of those infected. Over time, other symptoms were recognized, including the appearance of skin lesions. Initial reports of skin manifestations were documented by Italian dermatologists, probably because Italy was the first European country to be severely affected by the pandemic. The general clinical presentation, course, and outcome of SARS-CoV-2 infection in children differ from that in adults. In studies carried out during the first wave of the pandemic, it was observed that from 20.4% to 45% of patients with confirmed SARS-CoV-2 infection had presented skin manifestations, the maculopapular rash being the most frequently described. Subsequently, other studies classified the types of eruption attributable to the disease and related them to the stages and severity of the infection [1-2].

In a rather simplified way, cutaneous manifestations have been separated into two forms in terms of pathophysiology: inflammatory, as an immune response to viral nucleotides, and vascular, secondary to phenomena of vasculitis, vasculopathy, and thrombosis. Clinically, the patterns of dermatological manifestations associated with SARS-CoV-2 infection could be classified into four categories: exanthema (varicella-like, papulo-vesicular, and morbilliform eruptions), vascular (chilblain, purpuric/petechial, and livedoid-like lesions), urticarial and acropapular rash, other skin manifestations to be taken into account are skin adverse reactions to drugs prescribed for the treatment of COVID-19. Despite the multiple studies that have reported eruptions related to SARS-CoV-2 infection during the first wave, due to healthcare pressure and insufficient diagnostic tests at that time, few studies adequately documented this relationship. Most only performed PCR or serology on a percentage of the included patients, while others did not refer to the microbiological method used [3].

Regarding the mechanism of lesion production, the risk of an organ developing a SARS-CoV-2 infection is determined by the presence of functional viral receptors ACE2 (angiotensin-converting enzyme 2) and TMPRSS2 (transmembrane protease serine 2). The direct action of the virus on the skin could influence its appearance, different studies have shown that the ACE-2 receptor is present in the endothelial cells of the blood vessels located in the basal layer of the epidermis, as well as in hair follicles, they have not been found in keratinocytes or melanocytes, which means that the virus cannot penetrate and infect the skin directly and mainly. Skin involvement is indirect and is caused by infection of the endothelial cells of the dermal vessels [4].

Viral activation of mast cells and basophils could account for lesions such as urticaria and rashes. Regarding vascular phenomena, the most studied lesions are of the pernio erythema type, it is believed that the pernio erythema associated with COVID-19 is also the product of an exaggerated immune response with type I interferon signaling, which is transcendental for viral eradication, but with a generalized highly inflammatory reaction. In critical patients with purpura, vascular thrombosis in the skin and other organs would be associated with a minimal interferon response, allowing excessive viral replication, with the release of viral proteins that are located in the extrapulmonary endothelium and trigger extensive complement activation. All of the above has been elucidated by detecting the virus using electron microscopy and PCR techniques in skin biopsies; generalized endothelial infection by SARS-CoV-2 could play a pathogenic role in severe forms of COVID-19. It has recently been suggested that SARS-CoV-2 could induce the reactivation of other latent viruses, such as HHV-6, which is actually responsible for some skin manifestations initially attributed to COVID-19, such as rashes and pityriasis rosea-like eruptions [5].

Establishing the cause-effect relationship between SARSCoV- 2 infection and skin manifestations has been difficult, and few studies have demonstrated immunolabeled SARS-CoV-2 antigens in skin biopsies under immunohistochemistry. The low availability of immunomarkers is another factor that has had a negative influence on establishing this relationship. The works that have studied immunomarkers for SARS-CoV-2 have shown positivity in endothelial cells and epithelial cells of eccrine glands, even coronavirus particles have been found in the cytoplasm of endothelial cells in electron microscopy [6].

The clinical and histopathological characteristics of the cutaneous manifestations by SARS-CoV-2 are similar to other forms of infectious eruptions, therefore this entity can be added to the list of previously known simulating diseases, such as the case of syphilis, due to its wide repertoire of skin manifestations. Cutaneous manifestations are therefore nonspecific and should be carefully evaluated and attributed to COVID-19 only after ruling out other differential diagnoses. In case of generalized urticarial and maculopapular eruptions, the differential diagnosis should be made with other infectious diseases or adverse drug reactions [7].


  1. Andina D, Belloni Fortina A, Bodemer C, Bonifazi E, Chiriac A, et al. (2021) Skin manifestations of COVID-19 in children: Part 3. Clinical and experimental dermatology 46(3): 462-472.
  2. Seque CA, Enokihara M, Porro AM, Tomimori J (2022) Skin manifestations associated with COVID-19. A Bras Dermatol 97(1): 75-88.
  3. Suchonwanit P, Leerunyakul K, Kositkuljorn C (2020) Cutaneous manifestations in COVID-19: Lessons learned from current evidence. Journal of the American Academy of Dermatology 83(1): e57-e60.
  4. Magro CM, Mulvey JJ, Laurence J, Sanders S, Crowson AN, et al. (2021) The differing pathophysiologies that underlie COVID-19-associated perniosis and thrombotic retiform purpura: a case series. The British Journal of Dermatology 184(1): 141-150.
  5. Abadías Granado I, Navarro Bielsa A, Morales Callaghan AM, Roc L, Suso Estívalez CC, et al. (2021) COVID-19-associated cutaneous manifestations: does human herpesvirus 6 play an aetiological role? The British Journal of Dermatology 184(6): 1187-1190.
  6. Fattori A, Cribier B, Chenard MP, Mitcov M, Mayeur S, et al. (2021) Cutaneous manifestations in patients with coronavirus disease 2019: clinical and histological findings. Human Pathology 107: 39-45.
  7. McGonagle D, Bridgewood C, Ramanan AV, Meaney J, Watad A (2021) COVID-19 vasculitis and novel vasculitis mimics. The Lancet Rheumatol 3(3): e224-e233.

© 2022 Jimmy Steven. This is an open access article distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and build upon your work non-commercially.